Home › Research › Cognitive tests and assessment
Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials
Yang G, Wang Y, Tian J, Liu JP.. PloS one, 2013-09-23
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Huperzine A is a Chinese herb extract used for Alzheimer's disease. We conducted this review to evaluate the beneficial and harmful effect of Huperzine A for treatment of Alzheimer's disease. Methods We searched for randomized clinical trials (RCTs) of Huperzine A for Alzheimer's disease in PubMed, Cochrane Library, and four major Chinese electronic databases from their inception to June 2013.
What this study adds
Evidence grade: High
This is a pooled review of 1,823 participants. This meta-analysis of 20 randomized trials examined the benefits and harms of Huperzine A, a Chinese herb extract, for treating Alzheimer's disease. It reviews existing trial evidence on a treatment but does not establish a cure or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Yang, G., Wang, Y., Tian, J., & Liu, J. P. (2013). Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials. PloS one. https://doi.org/10.1371/journal.pone.0074916
Vancouver
Yang G, Wang Y, Tian J, Liu JP. Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials. PloS one. 2013. doi:10.1371/journal.pone.0074916. PMID: 24086396.
BibTeX
@article{yang2013-24086396,
author = {Yang, G. and Wang, Y. and Tian, J. and Liu, J. P.},
title = {{Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials}},
journal = {PloS one},
year = {2013},
doi = {10.1371/journal.pone.0074916},
pmid = {24086396},
url = {https://doi.org/10.1371/journal.pone.0074916}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- We conducted this review to evaluate the beneficial and harmful effect of Huperzine A for treatment of Alzheimer's disease.
- Methods We searched for randomized clinical trials (RCTs) of Huperzine A for Alzheimer's disease in PubMed, Cochrane Library, and four major Chinese electronic databases from their inception to June 2013.
- We performed meta-analyses using RevMan 5.1 software.
- Results 20 RCTs including 1823 participants were included.
Why it matters
This meta-analysis of 20 randomized trials examined the benefits and harms of Huperzine A, a Chinese herb extract, for treating Alzheimer's disease. It reviews existing trial evidence on a treatment but does not establish a cure or prevention.
Study details
- Study designmeta-analysis
- Participants1,823
- Evidence strengthHigh
How this study scored 66/100
Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (PloS one) |
| Journal's citation record | 4 / 4 | PLoS ONE: journal h-index 594 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A meta-analysis pooling many studies |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2013 — within 20 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,823 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 5 / 7 | Cited 241 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 16.1 citations a year over 15 year(s) since 2013 |
| Impact for its field and year | 2 / 6 | Cited 2.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 2 / 4 | Cited 39 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Jianping Liu: h-index 69 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Beijing University of Chinese Medicine: institution h-index 298 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 24086396) |
| Free to read | 2 / 2 | Free to read |
| Total | 66 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Cognitive tests and assessment from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.